Physician profile
Sasmit Roy
NPI 1053728857
$1,273.00
in general payments reported to CMS, 2019-2025
10 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.51 · 2021: $199 · 2022: $142 · 2023: $215 · 2024: $221 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811 · Education: $25.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.68 |
| Education | $25.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $230.69 | 2021-2025 | Terlivaz |
| Novo Nordisk INC | $184.61 | 2025 | Wegovy, Ozempic |
| Otsuka America Pharmaceutical, INC. | $169.76 | 2020-2023 | Jynarque |
| Vifor Pharma, INC. | $160.18 | 2021-2023 | Korsuva, Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $154.21 | 2021-2025 | |
| Travere Therapeutics, INC. | $116.62 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $109.72 | 2024 | |
| Aurinia Pharma U.S., INC. | $72.71 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $57.34 | 2022 | |
| Bard Peripheral Vascular, INC. | $17.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasmit Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.